Clinical Trial Update: Effects of Somatostatin on Liver in ADPKD [Phase 2, Phase 3]

View source ↗

Summary

A report on the completion of a Phase 2/3 clinical trial evaluating somatostatin for liver involvement in autosomal dominant polycystic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Somatostatin (somatostatin)

Snippet

Sponsor: Federico II University | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2, Phase 3 | Status: COMPLETED